van Engelenburg FA - Search Results

1

Differential sensitivities of pathogens in red cell concentrates to Tri-P(4)-photoinactivation.

Trannoy LL, Terpstra FG, de Korte D, Lagerberg JW, Verhoeven AJ, Brand A, van Engelenburg FA. Trannoy LL, et al. Among authors: van engelenburg fa. Vox Sang. 2006 Aug;91(2):111-8. doi: 10.1111/j.1423-0410.2006.00791.x. Vox Sang. 2006. PMID: 16907871

2

Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.

Terpstra FG, Parkkinen J, Tölö H, Koenderman AH, Ter Hart HG, von Bonsdorff L, Törmä E, van Engelenburg FA. Terpstra FG, et al. Among authors: van engelenburg fa. Vox Sang. 2006 Jan;90(1):21-32. doi: 10.1111/j.1423-0410.2005.00710.x. Vox Sang. 2006. PMID: 16359352

3

Additive effects of dipyridamole and Trolox in protecting human red cells during photodynamic treatment.

Besselink GA, van Engelenburg FA, Ebbing IG, Hilarius PM, de Korte D, Verhoeven AJ. Besselink GA, et al. Among authors: van engelenburg fa. Vox Sang. 2003 Jul;85(1):25-30. doi: 10.1046/j.1423-0410.2003.00318.x. Vox Sang. 2003. PMID: 12823727

4

Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates.

Terpstra FG, van 't Wout AB, Schuitemaker H, van Engelenburg FA, Dekkers DW, Verhaar R, de Korte D, Verhoeven AJ. Terpstra FG, et al. Among authors: van engelenburg fa. Transfusion. 2008 Feb;48(2):304-13. doi: 10.1111/j.1537-2995.2007.01524.x. Epub 2007 Nov 19. Transfusion. 2008. PMID: 18028277

5

The band III ligand dipyridamole protects human RBCs during photodynamic treatment while extracellular virus inactivation is not affected.

Besselink GA, Van Engelenburg FA, Korsten HG, Blokker DE, Lagerberg JW, Brand A, De Korte D, Verhoeven AJ. Besselink GA, et al. Among authors: van engelenburg fa. Transfusion. 2002 Jun;42(6):728-33. doi: 10.1046/j.1537-2995.2002.00124.x. Transfusion. 2002. PMID: 12147025

6

Viral safety of C1-inhibitor NF.

Terpstra FG, Kleijn M, Koenderman AH, Over J, van Engelenburg FA, Schuitemaker H, van 't Wout AB. Terpstra FG, et al. Among authors: van engelenburg fa. Biologicals. 2007 Jun;35(3):173-81. doi: 10.1016/j.biologicals.2006.08.005. Epub 2006 Oct 30. Biologicals. 2007. PMID: 17071103

7

The virucidal spectrum of a high concentration alcohol mixture.

van Engelenburg FA, Terpstra FG, Schuitemaker H, Moorer WR. van Engelenburg FA, et al. J Hosp Infect. 2002 Jun;51(2):121-5. doi: 10.1053/jhin.2002.1211. J Hosp Infect. 2002. PMID: 12090799

8

Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process.

Bos OJ, Sunyé DG, Nieuweboer CE, van Engelenburg FA, Schuitemaker H, Over J. Bos OJ, et al. Among authors: van engelenburg fa. Biologicals. 1998 Dec;26(4):267-76. doi: 10.1006/biol.1998.0148. Biologicals. 1998. PMID: 10403030

9

Inhibition of HIV-1 IIIB and clinical isolates by human parotid, submandibular, sublingual and palatine saliva.

Bolscher JG, Nazmi K, Ran LJ, van Engelenburg FA, Schuitemaker H, Veerman EC, Nieuw Amerongen AV. Bolscher JG, et al. Among authors: van engelenburg fa. Eur J Oral Sci. 2002 Apr;110(2):149-56. doi: 10.1034/j.1600-0722.2002.11175.x. Eur J Oral Sci. 2002. PMID: 12013559

10

Standards for the assay of Creutzfeldt-Jakob disease specimens.

Minor P, Newham J, Jones N, Bergeron C, Gregori L, Asher D, van Engelenburg F, Stroebel T, Vey M, Barnard G, Head M, The Who Working Group On International Reference Materials For The Diagnosis And Study Of Transmissible Spongiform Encephalopathies. Minor P, et al. J Gen Virol. 2004 Jun;85(Pt 6):1777-1784. doi: 10.1099/vir.0.79959-0. J Gen Virol. 2004. PMID: 15166463

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

17 results

Search Page